SubHero Banner
Text

Tecentriq® (atezolizumab) – Expanded indication

December 6, 2018 - Genentech announced the FDA approval of Tecentriq (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel, and carboplatin, for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations.

Download PDF